MAPT and Alzheimer disease: The tracer [18F]THK5317 (also known as (S)-[18F]THK5117) has high target specificity and selectivity [16] and favorable pharmacokinetic properties for non-invasive imaging of tau pathology [17], with good discrimination of AD patients from healthy controls in in vivo PET studies [18, 19].